Survival of breast cancer patients according to changes in expression of selected markers between primary tumor and lymph node metastases. (March 2016)

• Record Type: Journal Article
• Authors: Adamczyk, Agnieszka; Niemiec, Joanna; Ambicka, Aleksandra; Mucha-Małecka, Anna; Ryś, Janusz; Mituś, Jerzy; Wysocki, Wojciech M; Cichocka, Anna; Jakubowicz, Jerzy
• Is Part Of: Biomarkers in medicine. Volume 10:Number 3(2016)
• Page Start: 219
• Page End: 228
• Publication Date: 2016-03
• Subjects: breast carcinoma -- changes in proteins expression -- lymph node metastases -- primary tumor; Biochemical markers -- Periodicals; 610.28
• DOI: 10.2217/bmm.15.123
• Languages: English
• ISSNs: 1752-0363

Abstract

Background: The differences between primary and metastatic tumor cells might be important for treatment selection and prognostication.Materials & methods: Expression of ER, PR, HER2, CK5/6, EGFR, Ki-67, Ep-CAM, P-cadherin, CD24, CD44, ALDH was assessed immunohistochemically in primary tumor (T) and corresponding synchronous nodal metastases (LNM) in 156 invasive ductal breast cancer patients (T ≥1, N ≥1, M0).Results: Independent negative prognostic factors for disease-free survival were pN3, ALDH immunopositivity in LNM, nonluminal A subtype in LNM, reduction of Ep-CAM expression in LNM, lack of changes or enhancement of CK5/6 and ALDH expression in LNM.Discussion: Our results suggest that in some cases expression of markers in lymph node metastases might bring additional prognostic information to that obtained from primary tumor.